TransCode Therapeutics (NASDAQ:RNAZ) Trading Down 2.4% – Here’s Why

Shares of TransCode Therapeutics Inc. (NASDAQ:RNAZ) were down 2.4% during mid-day trading on Monday . The company traded as low as $1.65 and last traded at $1.65. Approximately 20,405 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 85,972 shares. The stock had previously closed at $1.69.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TransCode Therapeutics in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

TransCode Therapeutics Stock Down 2.4%

The stock’s 50 day moving average is $4.56 and its 200 day moving average is $6.50. The firm has a market cap of $27.93 million, a price-to-earnings ratio of -0.03 and a beta of 1.16.

TransCode Therapeutics (NASDAQ:RNAZ) last announced its earnings results on Friday, August 14th. The company reported ($7.17) earnings per share for the quarter.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.